GlassScriptPhysician profile
Aspen I Ralph
NPI 1548264450
$2,231.81
in general payments reported to CMS, 2019-2025
27 companies · $57.09 in 2025
The $57.09 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $456 · 2021: $465 · 2022: $379 · 2024: $227 · 2025: $57.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $311.69 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $283.17 | 2020-2022 | |
| Abbvie INC. | $168.81 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $101.16 | 2019-2022 | |
| Pfizer INC. | $97.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $82.54 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.08 | 2019-2022 | |
| Amarin Pharma, INC. | $58.28 | 2020-2021 | |
| Abbott Laboratories | $57.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $37.65 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $36.68 | 2025 | Zenpep |
| Lilly USA, LLC | $33.15 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $31.08 | 2021-2022 | |
| Astellas Pharma US INC | $30.79 | 2019-2020 | |
| Exact Sciences Corporation | $20.41 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $19.47 | 2021 | |
| Phadia US INC. | $19.17 | 2021 | |
| Esperion Therapeutics, INC. | $19.14 | 2021 | |
| Amgen INC. | $19.00 | 2019 | |
| Allergan, INC. | $15.34 | 2019 | |
| Ibsa Pharma INC. | $14.63 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.28 | 2021 | |
| Acella Pharmaceuticals, LLC | $11.56 | 2020 | |
| Horizon Therapeutics Plc | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aspen Ralph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.